Company news
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) news
Phathom Pharmaceuticals, Inc. news releases on 6ix. Latest, Mar 1, 2022: Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results…
Press releases — page 3
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
February 28, 2022
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
February 8, 2022
Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
November 22, 2021
Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
November 11, 2021
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
November 7, 2021
Phathom Pharmaceuticals Withdraws Public Offering
October 26, 2021
Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock
October 25, 2021
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
October 23, 2021
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
October 20, 2021
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
October 17, 2021
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
September 26, 2021
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
September 19, 2021
Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection
September 7, 2021
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
August 30, 2021
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
August 9, 2021
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
August 4, 2021
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
August 1, 2021
Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 24, 2021
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
May 10, 2021
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
May 5, 2021
Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
April 28, 2021
Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference
April 5, 2021
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
March 29, 2021
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
January 18, 2021
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock
December 14, 2020
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
December 13, 2020
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
November 29, 2020
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
November 26, 2020
Phathom Pharmaceuticals to Host Virtual Investor Day
November 18, 2020
Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
November 12, 2020
Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials
November 9, 2020
Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference
September 8, 2020
Phathom Pharmaceuticals Reports Second Quarter 2020 Results
August 5, 2020
Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer
July 12, 2020
Phathom Pharmaceuticals Provides Clinical Trial Status Update
June 14, 2020
Phathom Pharmaceuticals to Present at Upcoming Investor Conferences
May 27, 2020
Phathom Pharmaceuticals Reports First Quarter 2020 Results
May 11, 2020
Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference
April 8, 2020
Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates
March 18, 2020
Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020
February 24, 2020
Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer
January 5, 2020
Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection
December 22, 2019
Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition
December 1, 2019
Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis
December 1, 2019
Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference
November 25, 2019
Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 24, 2019
Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 28, 2019